Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription

Articles published in PLoS One

Retrieve available abstracts of 312 articles:
HTML format

Single Articles

    January 2021
  1. QUAGLIA F, Krishn SR, Wang Y, Goodrich DW, et al
    Differential expression of alphaVbeta3 and alphaVbeta6 integrins in prostate cancer progression.
    PLoS One. 2021;16:e0244985.
    PubMed     Abstract available

  2. LABRECQUE MP, Brown LG, Coleman IM, Nguyen HM, et al
    Cabozantinib can block growth of neuroendocrine prostate cancer patient-derived xenografts by disrupting tumor vasculature.
    PLoS One. 2021;16:e0245602.
    PubMed     Abstract available

  3. OLDE HEUVEL J, de Wit-van der Veen BJ, Sinaasappel M, Slump CH, et al
    Early differences in dynamic uptake of 68Ga-PSMA-11 in primary prostate cancer: A test-retest study.
    PLoS One. 2021;16:e0246394.
    PubMed     Abstract available

  4. GUEST C, Harris R, Sfanos KS, Shrestha E, et al
    Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer.
    PLoS One. 2021;16:e0245530.
    PubMed     Abstract available

  5. WANG Y, Wang J, Tang Q, Ren G, et al
    Identification of UBE2C as hub gene in driving prostate cancer by integrated bioinformatics analysis.
    PLoS One. 2021;16:e0247827.
    PubMed     Abstract available

  6. KARLSSON AA, Hao S, Jauhiainen A, Elfstrom KM, et al
    The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
    PLoS One. 2021;16:e0246674.
    PubMed     Abstract available

  7. GRAYSON KA, Jyotsana N, Ortiz-Otero N, King MR, et al
    Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
    PLoS One. 2021;16:e0246733.
    PubMed     Abstract available

  8. JEONG JU, Nam TK, Song JY, Yoon MS, et al
    Favorable prognosis of patients who received adjuvant androgen deprivation therapy after radiotherapy achieving undetectable levels of prostate-specific antigen in high- or very high-risk prostate cancer.
    PLoS One. 2021;16:e0248461.
    PubMed     Abstract available

  9. LIMA CA, da Silva BEB, Hora EC, Lima MS, et al
    Trends in prostate cancer incidence and mortality to monitor control policies in a northeastern Brazilian state.
    PLoS One. 2021;16:e0249009.
    PubMed     Abstract available

  10. ZIAYEE F, Ullrich T, Blondin D, Irmer H, et al
    Impact of qualitative, semi-quantitative, and quantitative analyses of dynamic contrast-enhanced magnet resonance imaging on prostate cancer detection.
    PLoS One. 2021;16:e0249532.
    PubMed     Abstract available

  11. KHAIRNAR R, Pugh SL, Sandler HM, Lee WR, et al
    Mapping expanded prostate cancer index composite to EQ5D utilities to inform economic evaluations in prostate cancer: Secondary analysis of NRG/RTOG 0415.
    PLoS One. 2021;16:e0249123.
    PubMed     Abstract available

  12. CHUNG JW, Kim HT, Ha YS, Lee EH, et al
    Identification of a novel non-invasive biological marker to overcome the shortcomings of PSA in diagnosis and risk stratification for prostate cancer: Initial prospective study of developmental endothelial locus-1 protein.
    PLoS One. 2021;16:e0250254.
    PubMed     Abstract available

  13. ZHANG P, Tan X, Zhang D, Gong Q, et al
    Development and validation of a set of novel and robust 4-lncRNA-based nomogram predicting prostate cancer survival by bioinformatics analysis.
    PLoS One. 2021;16:e0249951.
    PubMed     Abstract available

  14. YADAV MP, Ballal S, Sahoo RK, Tripathi M, et al
    Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
    PLoS One. 2021;16:e0251375.
    PubMed     Abstract available

  15. SAIDOVA AA, Potashnikova DM, Tvorogova AV, Paklina OV, et al
    Myosin 1C isoform A is a novel candidate diagnostic marker for prostate cancer.
    PLoS One. 2021;16:e0251961.
    PubMed     Abstract available

  16. Retraction: Raf Kinase Inhibitor Protein (RKIP) Blocks Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Breast and Prostate Cancer.
    PLoS One. 2021;16:e0253350.

  17. LOUGHNEY L, McGowan R, O'Malley K, McCaffrey N, et al
    Perceptions of wellbeing and quality of life following participation in a community-based pre-operative exercise programme in men with newly diagnosed prostate cancer: A qualitative pilot study.
    PLoS One. 2021;16:e0253018.
    PubMed     Abstract available

  18. PAROL-KULCZYK M, Gzil A, Maciejewska J, Bodnar M, et al
    Clinicopathological significance of the EMT-related proteins and their interrelationships in prostate cancer. An immunohistochemical study.
    PLoS One. 2021;16:e0253112.
    PubMed     Abstract available

  19. KIM SI, Szeto AH, Morgan KP, Brower B, et al
    A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    PLoS One. 2021;16:e0253021.
    PubMed     Abstract available

  20. GUERRIERO I, Ramberg H, Sagini K, Ramirez-Garrastacho M, et al
    Implication of beta2-adrenergic receptor and miR-196a correlation in neurite outgrowth of LNCaP prostate cancer cells.
    PLoS One. 2021;16:e0253828.
    PubMed     Abstract available

  21. JIANG X, Renkema H, Smeitink J, Beyrath J, et al
    Sonlicromanol's active metabolite KH176m normalizes prostate cancer stem cell mPGES-1 overexpression and inhibits cancer spheroid growth.
    PLoS One. 2021;16:e0254315.
    PubMed     Abstract available

  22. SALMI F, Maachi F, Tazzite A, Aboutaib R, et al
    Next-generation sequencing of BRCA1 and BRCA2 genes in Moroccan prostate cancer patients with positive family history.
    PLoS One. 2021;16:e0254101.
    PubMed     Abstract available

  23. RUNDLE AG, Sadasivan SM, Chitale DA, Gupta NS, et al
    Racial differences in the systemic inflammatory response to prostate cancer.
    PLoS One. 2021;16:e0252951.
    PubMed     Abstract available

  24. ZHANG H, Doucette C, Yang H, Bandyopadhyay S, et al
    Risk of adverse pathological features for intermediate risk prostate cancer: Clinical implications for definitive radiation therapy.
    PLoS One. 2021;16:e0253936.
    PubMed     Abstract available

  25. BARRY DELONGCHAMPS N, Schull A, Anract J, Abecassis JP, et al
    Feasibility and safety of targeted focal microwave ablation of the index tumor in patients with low to intermediate risk prostate cancer: Results of the FOSTINE trial.
    PLoS One. 2021;16:e0252040.
    PubMed     Abstract available

  26. ARIK A, Dodd E, Cairns A, Streftaris G, et al
    Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality.
    PLoS One. 2021;16:e0253854.
    PubMed     Abstract available

  27. FALLARA G, Gedeborg R, Bill-Axelson A, Garmo H, et al
    A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
    PLoS One. 2021;16:e0255239.
    PubMed     Abstract available

    January 2020
  28. PICKLES K, Kazda L, Barratt A, McGeechan K, et al
    Evaluating two decision aids for Australian men supporting informed decisions about prostate cancer screening: A randomised controlled trial.
    PLoS One. 2020;15:e0227304.
    PubMed     Abstract available

  29. THOMSEN FB, Westerberg M, Garmo H, Robinson D, et al
    Prediction of metastatic prostate cancer by prostate-specific antigen in combination with T stage and Gleason Grade: Nationwide, population-based register study.
    PLoS One. 2020;15:e0228447.
    PubMed     Abstract available

  30. NAGAYA N, Nagata M, Lu Y, Kanayama M, et al
    Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
    PLoS One. 2020;15:e0226219.
    PubMed     Abstract available

  31. LUO Z, Farnham PJ
    Genome-wide analysis of HOXC4 and HOXC6 regulated genes and binding sites in prostate cancer cells.
    PLoS One. 2020;15:e0228590.
    PubMed     Abstract available

  32. LUCAS AR, Bitting RL, Fanning J, Isom S, et al
    Trajectories in muscular strength and physical function among men with and without prostate cancer in the health aging and body composition study.
    PLoS One. 2020;15:e0228773.
    PubMed     Abstract available

  33. LIU JM, Liu YP, Chuang HC, Wu CT, et al
    Androgen deprivation therapy for prostate cancer and the risk of hematologic disorders.
    PLoS One. 2020;15:e0229263.
    PubMed     Abstract available

  34. MEHTALA J, Zong J, Vassilev Z, Brobert G, et al
    Overall survival and second primary malignancies in men with metastatic prostate cancer.
    PLoS One. 2020;15:e0227552.
    PubMed     Abstract available

  35. BEKSISA J, Getinet T, Tanie S, Diribi J, et al
    Survival and prognostic determinants of prostate cancer patients in Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A retrospective cohort study.
    PLoS One. 2020;15:e0229854.
    PubMed     Abstract available

  36. WANG Z, Deng T, Long X, Lin X, et al
    Methylation of SRD5A2 promoter predicts a better outcome for castration-resistant prostate cancer patients undergoing androgen deprivation therapy.
    PLoS One. 2020;15:e0229754.
    PubMed     Abstract available

  37. ADIKARI A, de Silva D, Ranasinghe WKB, Bandaragoda T, et al
    Can online support groups address psychological morbidity of cancer patients? An artificial intelligence based investigation of prostate cancer trajectories.
    PLoS One. 2020;15:e0229361.
    PubMed     Abstract available

  38. ZOU Y, Tang F, Talbert JC, Ng CM, et al
    Using medical claims database to develop a population disease progression model for leuprorelin-treated subjects with hormone-sensitive prostate cancer.
    PLoS One. 2020;15:e0230571.
    PubMed     Abstract available

  39. JAVAID S, Saad SM, Zafar H, Malik R, et al
    Thymidine phosphorylase and prostrate cancer cell proliferation inhibitory activities of synthetic 4-hydroxybenzohydrazides: In vitro, kinetic, and in silico studies.
    PLoS One. 2020;15:e0227549.
    PubMed     Abstract available

  40. STEINER B, Ferrucci LM, Mirabello L, Lan Q, et al
    Association between coffee drinking and telomere length in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.
    PLoS One. 2020;15:e0226972.
    PubMed     Abstract available

  41. ULYTE A, Wei W, Dressel H, Gruebner O, et al
    Variation of colorectal, breast and prostate cancer screening activity in Switzerland: Influence of insurance, policy and guidelines.
    PLoS One. 2020;15:e0231409.
    PubMed     Abstract available

  42. DALY C, Logan B, Breeyear J, Whitaker K, et al
    Tks5 SH3 domains exhibit differential effects on invadopodia development.
    PLoS One. 2020;15:e0227855.
    PubMed     Abstract available

  43. HEO JE, Lee JS, Goh HJ, Jang WS, et al
    Urethral realignment with maximal urethral length and bladder neck preservation in robot-assisted radical prostatectomy: Urinary continence recovery.
    PLoS One. 2020;15:e0227744.
    PubMed     Abstract available

  44. MEDHIN LB, Achila OO, Syum BE, Gebremichael KH, et al
    Incidence of prostate cancer in Eritrea: Data from the National Health Laboratory, Orotta Referral Hospital and Sembel Hospital 2011-2018.
    PLoS One. 2020;15:e0232091.
    PubMed     Abstract available

  45. SINGH S, McDonald JT, Ilie G, Adisesh A, et al
    An examination of the association between lifetime history of prostate and pancreatic cancer diagnosis and occupation in a population sample of Canadians.
    PLoS One. 2020;15:e0227622.
    PubMed     Abstract available

  46. Retraction: Prostate Cancer Cell Lines under Hypoxia Exhibit Greater Stem-Like Properties.
    PLoS One. 2020;15:e0233203.

  47. MURAKAMI Y, Magome T, Matsumoto K, Sato T, et al
    Fully automated dose prediction using generative adversarial networks in prostate cancer patients.
    PLoS One. 2020;15:e0232697.
    PubMed     Abstract available

  48. NGO D, Baumgartner R, Mt-Isa S, Feng D, et al
    Bayesian credible subgroup identification for treatment effectiveness in time-to-event data.
    PLoS One. 2020;15:e0229336.
    PubMed     Abstract available

  49. BRASIL DA COSTA FH, Lewis MS, Truong A, Carson DD, et al
    SULF1 suppresses Wnt3A-driven growth of bone metastatic prostate cancer in perlecan-modified 3D cancer-stroma-macrophage triculture models.
    PLoS One. 2020;15:e0230354.
    PubMed     Abstract available

  50. CHAURASIYA S, Widmann S, Botero C, Lin CY, et al
    Estrogen receptor beta exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity.
    PLoS One. 2020;15:e0226057.
    PubMed     Abstract available

  51. MACAGNO A, Athanasiou A, Wittig A, Huber R, et al
    Analytical performance of thrombospondin-1 and cathepsin D immunoassays part of a novel CE-IVD marked test as an aid in the diagnosis of prostate cancer.
    PLoS One. 2020;15:e0233442.
    PubMed     Abstract available

  52. GRAHAM LS, Montgomery B, Cheng HH, Yu EY, et al
    Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.
    PLoS One. 2020;15:e0233260.
    PubMed     Abstract available

  53. RIKKERT LG, de Rond L, van Dam A, van Leeuwen TG, et al
    Detection of extracellular vesicles in plasma and urine of prostate cancer patients by flow cytometry and surface plasmon resonance imaging.
    PLoS One. 2020;15:e0233443.
    PubMed     Abstract available

  54. SENNOUNE SR, Nelius T, Jarvis C, Pruitt K, et al
    The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.
    PLoS One. 2020;15:e0234078.
    PubMed     Abstract available

  55. CHEN MM, Jahn JL, Barber JR, Han M, et al
    Clinical stage provides useful prognostic information even after pathological stage is known for prostate cancer in the PSA era.
    PLoS One. 2020;15:e0234391.
    PubMed     Abstract available

  56. HUSAINI Y, Tsai VW, Manandhar R, Zhang HP, et al
    Growth differentiation factor-15 slows the growth of murine prostate cancer by stimulating tumor immunity.
    PLoS One. 2020;15:e0233846.
    PubMed     Abstract available

  57. SHIN D, Shim SR, Kim CH
    Changes in Beck Depression Inventory scores in prostate cancer patients undergoing androgen deprivation therapy or prostatectomy.
    PLoS One. 2020;15:e0234264.
    PubMed     Abstract available

  58. PACKEISER EM, Hewicker-Trautwein M, Thiemeyer H, Mohr A, et al
    Characterization of six canine prostate adenocarcinoma and three transitional cell carcinoma cell lines derived from primary tumor tissues as well as metastasis.
    PLoS One. 2020;15:e0230272.
    PubMed     Abstract available

  59. SILTARI A, Murtola TJ, Talala K, Taari K, et al
    Antihypertensive drug use and prostate cancer-specific mortality in Finnish men.
    PLoS One. 2020;15:e0234269.
    PubMed     Abstract available

  60. WU YT, Chiang PH
    Cohort study of high-intensity focused ultrasound in the treatment of localised prostate cancer treatment: Medium-term results from a single centre.
    PLoS One. 2020;15:e0236026.
    PubMed     Abstract available

  61. RHO MJ, Park J, Moon HW, Lee C, et al
    Dr. Answer AI for prostate cancer: Clinical outcome prediction model and service.
    PLoS One. 2020;15:e0236553.
    PubMed     Abstract available

  62. ARIK A, Dodd E, Streftaris G
    Cancer morbidity trends and regional differences in England-A Bayesian analysis.
    PLoS One. 2020;15:e0232844.
    PubMed     Abstract available

  63. DAOUK R, Bahmad HF, Saleh E, Monzer A, et al
    Genome-wide gene expression analysis of a murine model of prostate cancer progression: Deciphering the roles of IL-6 and p38 MAPK as potential therapeutic targets.
    PLoS One. 2020;15:e0237442.
    PubMed     Abstract available

  64. LYNCH SM, Handorf E, Sorice KA, Blackman E, et al
    The effect of neighborhood social environment on prostate cancer development in black and white men at high risk for prostate cancer.
    PLoS One. 2020;15:e0237332.
    PubMed     Abstract available

  65. ERB HHH, Bodenbender J, Handle F, Diehl T, et al
    Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer.
    PLoS One. 2020;15:e0237248.
    PubMed     Abstract available

    Secretome analysis reveals upregulated granzyme B in human androgen-repressed prostate cancer cells with mesenchymal and invasive phenotype.
    PLoS One. 2020;15:e0237222.
    PubMed     Abstract available

  67. PAPANDRIANOS N, Papageorgiou E, Anagnostis A, Papageorgiou K, et al
    Bone metastasis classification using whole body images from prostate cancer patients based on convolutional neural networks application.
    PLoS One. 2020;15:e0237213.
    PubMed     Abstract available

  68. YAMADA Y, Teshima T, Fujimura T, Sato Y, et al
    Comparison of perioperative outcomes in elderly (age >== 75 years) vs. younger men undergoing robot-assisted radical prostatectomy.
    PLoS One. 2020;15:e0234113.
    PubMed     Abstract available

  69. SANTOS-SANCHEZ V, Cordoba-Dona JA, Viciana F, Escolar-Pujolar A, et al
    Geographical variations in cancer mortality and social inequalities in southern Spain (Andalusia). 2002-2013.
    PLoS One. 2020;15:e0233397.
    PubMed     Abstract available

  70. STROOMBERG HV, Jorgensen A, Brasso K, Nielsen JE, et al
    Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients.
    PLoS One. 2020;15:e0238814.
    PubMed     Abstract available

  71. GROARKE A, Curtis R, Skelton J, Groarke JM, et al
    Quality of life and adjustment in men with prostate cancer: Interplay of stress, threat and resilience.
    PLoS One. 2020;15:e0239469.
    PubMed     Abstract available

  72. ALADWANI M, Lophatananon A, Robinson F, Rahman A, et al
    Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study.
    PLoS One. 2020;15:e0238928.
    PubMed     Abstract available

  73. MISHRA MV, Thayer WM, Janssen E, Hoppe B, et al
    Patient preferences for reducing bowel adverse events following prostate radiotherapy.
    PLoS One. 2020;15:e0235616.
    PubMed     Abstract available

  74. HONG S, Youk T, Lee SJ, Kim KM, et al
    Bone metastasis and skeletal-related events in patients with solid cancer: A Korean nationwide health insurance database study.
    PLoS One. 2020;15:e0234927.
    PubMed     Abstract available

  75. CARLSON AS, Acevedo RI, Lim DM, Gulati R, et al
    Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.
    PLoS One. 2020;15:e0239686.
    PubMed     Abstract available

  76. GONCU B, Sevgi E, Kizilarslan Hancer C, Gokay G, et al
    Differential anti-proliferative and apoptotic effects of lichen species on human prostate carcinoma cells.
    PLoS One. 2020;15:e0238303.
    PubMed     Abstract available

  77. YONG C, Moose DL, Bannick N, Gutierrez WR, et al
    Locally invasive, castrate-resistant prostate cancer in a Pten/Trp53 double knockout mouse model of prostate cancer monitored with non-invasive bioluminescent imaging.
    PLoS One. 2020;15:e0232807.
    PubMed     Abstract available

  78. FIORICA PN, Schubert R, Morris JD, Abdul Sami M, et al
    Multi-ethnic transcriptome-wide association study of prostate cancer.
    PLoS One. 2020;15:e0236209.
    PubMed     Abstract available

  79. LI AH, Palmer KS, Taljaard M, Paterson JM, et al
    Effects of quality-based procedure hospital funding reform in Ontario, Canada: An interrupted time series study.
    PLoS One. 2020;15:e0236480.
    PubMed     Abstract available

  80. SANDEMAN K, Eineluoto JT, Pohjonen J, Erickson A, et al
    Prostate MRI added to CAPRA, MSKCC and Partin cancer nomograms significantly enhances the prediction of adverse findings and biochemical recurrence after radical prostatectomy.
    PLoS One. 2020;15:e0235779.
    PubMed     Abstract available

  81. MEIJER D, Jansen BHE, Wondergem M, Bodar YJL, et al
    Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
    PLoS One. 2020;15:e0239414.
    PubMed     Abstract available

  82. SARIISIK E, Zistl D, Docheva D, Schilling AF, et al
    Inadequate tissue mineralization promotes cancer cell attachment.
    PLoS One. 2020;15:e0237116.
    PubMed     Abstract available

  83. SONG Y, Zhang J, Zhang YD, Hou Y, et al
    FeAture Explorer (FAE): A tool for developing and comparing radiomics models.
    PLoS One. 2020;15:e0237587.
    PubMed     Abstract available

  84. Correction: MicroRNA-302a Suppresses Tumor Cell Proliferation by Inhibiting AKT in Prostate Cancer.
    PLoS One. 2020;15:e0241462.
    PubMed     Abstract available

  85. KALINAUSKAITE G, Senger C, Kluge A, Furth C, et al
    68Ga-PSMA-PET/CT-based radiosurgery and stereotactic body radiotherapy for oligometastatic prostate cancer.
    PLoS One. 2020;15:e0240892.
    PubMed     Abstract available

  86. KATONGOLE P, Sande OJ, Yusuf M, Joloba M, et al
    Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2015 and 2019 at the Uganda Cancer Institute.
    PLoS One. 2020;15:e0236458.
    PubMed     Abstract available

  87. ZWAANS BMM, Nicolai HE, Chancellor MB, Lamb LE, et al
    Prostate cancer survivors with symptoms of radiation cystitis have elevated fibrotic and vascular proteins in urine.
    PLoS One. 2020;15:e0241388.
    PubMed     Abstract available

  88. BAIO G, Fabbi M, Cilli M, Rosa F, et al
    Manganese-enhanced MRI (MEMRI) in breast and prostate cancers: Preliminary results exploring the potential role of calcium receptors.
    PLoS One. 2020;15:e0224414.
    PubMed     Abstract available

  89. SINGH JP, Dagar M, Dagar G, Kumar S, et al
    Activation of GPR56, a novel adhesion GPCR, is necessary for nuclear androgen receptor signaling in prostate cells.
    PLoS One. 2020;15:e0226056.
    PubMed     Abstract available

  90. HAN C, Yu G, Mao Y, Song S, et al
    LPCAT1 enhances castration resistant prostate cancer progression via increased mRNA synthesis and PAF production.
    PLoS One. 2020;15:e0240801.
    PubMed     Abstract available

  91. NICHOLAS TR, Meng J, Greulich BM, Morris TS, et al
    --A high-throughput screen identifies inhibitors of the interaction between the oncogenic transcription factor ERG and the cofactor EWS.
    PLoS One. 2020;15:e0238999.
    PubMed     Abstract available

  92. TAKAKUSAGI Y, Oike T, Kano K, Anno W, et al
    Prostate-specific antigen dynamics after neoadjuvant androgen-deprivation therapy and carbon ion radiotherapy for prostate cancer.
    PLoS One. 2020;15:e0241636.
    PubMed     Abstract available

  93. MCNABB E, Al-Mahrouki A, Law N, McKay S, et al
    Ultrasound-stimulated microbubble radiation enhancement of tumors: Single-dose and fractionated treatment evaluation.
    PLoS One. 2020;15:e0239456.
    PubMed     Abstract available

  94. HOTKER AM, Bluthgen C, Rupp NJ, Schneider AF, et al
    Comparison of the PI-RADS 2.1 scoring system to PI-RADS 2.0: Impact on diagnostic accuracy and inter-reader agreement.
    PLoS One. 2020;15:e0239975.
    PubMed     Abstract available

  95. CUNNINGHAM J, Thuijsman F, Peeters R, Viossat Y, et al
    Optimal control to reach eco-evolutionary stability in metastatic castrate-resistant prostate cancer.
    PLoS One. 2020;15:e0243386.
    PubMed     Abstract available

  96. FRENDL DM, FitzGerald G, Epstein MM, Allison JJ, et al
    Predicting the 10-year risk of death from other causes in men with localized prostate cancer using patient-reported factors: Development of a tool.
    PLoS One. 2020;15:e0240039.
    PubMed     Abstract available

  97. BRADY L, Hayes B, Sheill G, Baird AM, et al
    Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial.
    PLoS One. 2020;15:e0243928.
    PubMed     Abstract available

  98. ISHIYAMA Y, Shimbo M, Iizuka J, Deshpande G, et al
    Association between prostate cancer characteristics and BRCA1/2-associated family cancer history in a Japanese cohort.
    PLoS One. 2020;15:e0244149.
    PubMed     Abstract available

  99. GEDEBORG R, Garmo H, Robinson D, Stattin P, et al
    Prescription-based prediction of baseline mortality risk among older men.
    PLoS One. 2020;15:e0241439.
    PubMed     Abstract available

  100. SHIM M, Bang WJ, Oh CY, Lee YS, et al
    Risk of dementia and Parkinson's disease in patients treated with androgen deprivation therapy using gonadotropin-releasing hormone agonist for prostate cancer: A nationwide population-based cohort study.
    PLoS One. 2020;15:e0244660.
    PubMed     Abstract available

  101. GEVAERT T, Van Eycke YR, Vanden Broeck T, Van Poppel H, et al
    The potential of tumour microenvironment markers to stratify the risk of recurrence in prostate cancer patients.
    PLoS One. 2020;15:e0244663.
    PubMed     Abstract available

  102. GONCU B, Sevgi E, Hancer CK, Gokay G, et al
    Correction: Differential anti-proliferative and apoptotic effects of lichen species on human prostate carcinoma cells.
    PLoS One. 2020;15:e0244831.
    PubMed     Abstract available

  103. KIM HY, Lee DS
    A role for phosphodiesterase type 5 inhibitors in remodelling the urinary bladder after radiation exposure.
    PLoS One. 2020;15:e0242006.
    PubMed     Abstract available

  104. DAHL HC, Kanchwala M, Thomas-Jardin SE, Sandhu A, et al
    Chronic IL-1 exposure drives LNCaP cells to evolve androgen and AR independence.
    PLoS One. 2020;15:e0242970.
    PubMed     Abstract available

  105. FALLARA G, Lissbrant IF, Styrke J, Montorsi F, et al
    Observational study on time on treatment with abiraterone and enzalutamide.
    PLoS One. 2020;15:e0244462.
    PubMed     Abstract available

    January 2019
  106. RODRIGUEZ-SANCHEZ L, Fernandez-Navarro P, Lopez-Abente G, Nunez O, et al
    Different spatial pattern of municipal prostate cancer mortality in younger men in Spain.
    PLoS One. 2019;14:e0210980.
    PubMed     Abstract available

  107. GOUPY F, Supiot S, Pasquier D, Latorzeff I, et al
    Intensity-modulated radiotherapy for prostate cancer with seminal vesicle involvement (T3b): A multicentric retrospective analysis.
    PLoS One. 2019;14:e0210514.
    PubMed     Abstract available

  108. JEGERLEHNER S, Chiolero A, Aujesky D, Rodondi N, et al
    Recent incidence and surgery trends for prostate cancer: Towards an attenuation of overdiagnosis and overtreatment?
    PLoS One. 2019;14:e0210434.
    PubMed     Abstract available

  109. KARLSSON A, Jauhiainen A, Gulati R, Eklund M, et al
    A natural history model for planning prostate cancer testing: Calibration and validation using Swedish registry data.
    PLoS One. 2019;14:e0211918.
    PubMed     Abstract available

  110. LAI CC, Huang PH, Wang FN, Shen SH, et al
    Histogram analysis of prostate cancer on dynamic contrast-enhanced magnetic resonance imaging: A preliminary study emphasizing on zonal difference.
    PLoS One. 2019;14:e0212092.
    PubMed     Abstract available

  111. ANTICO M, Prinsen P, Cellini F, Fracassi A, et al
    Real-time adaptive planning method for radiotherapy treatment delivery for prostate cancer patients, based on a library of plans accounting for possible anatomy configuration changes.
    PLoS One. 2019;14:e0213002.
    PubMed     Abstract available

  112. TAKAKUSAGI Y, Kawamura H, Okamoto M, Kaminuma T, et al
    Long-term outcome of hypofractionated intensity-modulated radiotherapy using TomoTherapy for localized prostate cancer: A retrospective study.
    PLoS One. 2019;14:e0211370.
    PubMed     Abstract available

  113. KANNAN A, Kirkman M, Ruseckaite R, Evans SM, et al
    Prostate cancer awareness, case-finding, and early diagnosis: Interviews with undiagnosed men in Australia.
    PLoS One. 2019;14:e0211539.
    PubMed     Abstract available

  114. LEUNG YK, Chan QK, Ng CF, Ma FM, et al
    Correction: Hsa-miRNA-765 as a Key Mediator for Inhibiting Growth, Migration and Invasion in Fulvestrant-Treated Prostate Cancer.
    PLoS One. 2019;14:e0214184.
    PubMed     Abstract available

  115. MARZORATI C, Monzani D, Mazzocco K, Pavan F, et al
    Predicting trajectories of recovery in prostate cancer patients undergone Robot-Assisted Radical Prostatectomy (RARP).
    PLoS One. 2019;14:e0214682.
    PubMed     Abstract available

  116. SEKHAR KR, Wang J, Freeman ML, Kirschner AN, et al
    Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.
    PLoS One. 2019;14:e0214670.
    PubMed     Abstract available

  117. SONG C, Byun SJ, Kim YS, Ahn H, et al
    Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis.
    PLoS One. 2019;14:e0215057.
    PubMed     Abstract available

  118. BRYZGUNOVA OE, Zaporozhchenko IA, Lekchnov EA, Amelina EV, et al
    Data analysis algorithm for the development of extracellular miRNA-based diagnostic systems for prostate cancer.
    PLoS One. 2019;14:e0215003.
    PubMed     Abstract available

  119. DERYCKE MS, Larson MC, Nair AA, McDonnell SK, et al
    An expanded variant list and assembly annotation identifies multiple novel coding and noncoding genes for prostate cancer risk using a normal prostate tissue eQTL data set.
    PLoS One. 2019;14:e0214588.
    PubMed     Abstract available

  120. MATZKIN H, Chen J, Agai R, Ziv-Baran T, et al
    Long-term biochemical progression-free survival following brachytherapy for prostate cancer: Further insight into the role of short-term androgen deprivation and intermediate risk group subclassification.
    PLoS One. 2019;14:e0215582.
    PubMed     Abstract available

  121. GUENTHER E, Klein N, Zapf S, Weil S, et al
    Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.
    PLoS One. 2019;14:e0215093.
    PubMed     Abstract available

  122. REDDY V, Iskander A, Hwang C, Divine G, et al
    Castration-resistant prostate cancer: Androgen receptor inactivation induces telomere DNA damage, and damage response inhibition leads to cell death.
    PLoS One. 2019;14:e0211090.
    PubMed     Abstract available

  123. ARMSTRONG AJ, Gupta S, Healy P, Kemeny G, et al
    Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.
    PLoS One. 2019;14:e0216934.
    PubMed     Abstract available

  124. KARUNASINGHE N, Symes E, Gamage A, Wang A, et al
    Interaction between leukocyte aldo-keto reductase 1C3 activity, genotypes, biological, lifestyle and clinical features in a prostate cancer cohort from New Zealand.
    PLoS One. 2019;14:e0217373.
    PubMed     Abstract available

  125. PALSDOTTIR T, Nordstrom T, Aly M, Lindberg J, et al
    Are Prostate Specific-Antigen (PSA) and age associated with the risk of ISUP Grade 1 prostate cancer? Results from 72 996 individual biopsy cores in 6 083 men from the Stockholm3 study.
    PLoS One. 2019;14:e0218280.
    PubMed     Abstract available

  126. ZECHMANN S, Di Gangi S, Kaplan V, Meier R, et al
    Time trends in prostate cancer screening in Swiss primary care (2010 to 2017) - A retrospective study.
    PLoS One. 2019;14:e0217879.
    PubMed     Abstract available

  127. JARRARD WE, Schultz A, Etheridge T, Damodaran S, et al
    Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection.
    PLoS One. 2019;14:e0218950.
    PubMed     Abstract available

  128. TOIVONEN J, Montoya Perez I, Movahedi P, Merisaari H, et al
    Radiomics and machine learning of multisequence multiparametric prostate MRI: Towards improved non-invasive prostate cancer characterization.
    PLoS One. 2019;14:e0217702.
    PubMed     Abstract available

  129. BRATTON BA, Maly IV, Hofmann WA
    Effect of polyunsaturated fatty acids on proliferation and survival of prostate cancer cells.
    PLoS One. 2019;14:e0219822.
    PubMed     Abstract available

  130. BURNELL SEA, Spencer-Harty S, Howarth S, Bodger O, et al
    Utilisation of the STEAP protein family in a diagnostic setting may provide a more comprehensive prognosis of prostate cancer.
    PLoS One. 2019;14:e0220456.
    PubMed     Abstract available

  131. BISHOP MR, Huskey ALW, Hetzel J, Merner ND, et al
    A research-based gene panel to investigate breast, ovarian and prostate cancer genetic risk.
    PLoS One. 2019;14:e0220929.
    PubMed     Abstract available

  132. XU L, Lee JR, Hao S, Ling XB, et al
    Improved detection of prostate cancer using a magneto-nanosensor assay for serum circulating autoantibodies.
    PLoS One. 2019;14:e0221051.
    PubMed     Abstract available

  133. JEON JM, Kwon OK, Na AY, Sung EJ, et al
    Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.
    PLoS One. 2019;14:e0220807.
    PubMed     Abstract available

  134. RADTKE JP, Giganti F, Wiesenfarth M, Stabile A, et al
    Prediction of significant prostate cancer in biopsy-naive men: Validation of a novel risk model combining MRI and clinical parameters and comparison to an ERSPC risk calculator and PI-RADS.
    PLoS One. 2019;14:e0221350.
    PubMed     Abstract available

  135. JEON JM, Kwon OK, Na AY, Sung EJ, et al
    Correction: Secretome profiling of PC3/nKR cells, a novel highly migrating prostate cancer subline derived from PC3 cells.
    PLoS One. 2019;14:e0222693.
    PubMed     Abstract available

  136. ZHANG W, Hu C, Wang X, Bai S, et al
    Role of GDF15 in methylseleninic acid-mediated inhibition of cell proliferation and induction of apoptosis in prostate cancer cells.
    PLoS One. 2019;14:e0222812.
    PubMed     Abstract available

  137. LEE GT, Rosenfeld JA, Kim WT, Kwon YS, et al
    TCF4 induces enzalutamide resistance via neuroendocrine differentiation in prostate cancer.
    PLoS One. 2019;14:e0213488.
    PubMed     Abstract available

  138. Expression of Concern: Resveratrol Enhances Antitumor Activity of TRAIL in Prostate Cancer Xenografts through Activation of FOXO Transcription Factor.
    PLoS One. 2019;14:e0223138.

  139. HUGHES S, Egger S, Carle C, Smith DP, et al
    Factors associated with the use of diet and the use of exercise for prostate cancer by long-term survivors.
    PLoS One. 2019;14:e0223407.
    PubMed     Abstract available

  140. KOZIKOWSKI M, Malewski W, Michalak W, Dobruch J, et al
    Clinical utility of MRI in the decision-making process before radical prostatectomy: Systematic review and meta-analysis.
    PLoS One. 2019;14:e0210194.
    PubMed     Abstract available

  141. TEOH JYC, Hirai HW, Ho JMW, Chan FCH, et al
    Global incidence of prostate cancer in developing and developed countries with changing age structures.
    PLoS One. 2019;14:e0221775.
    PubMed     Abstract available

  142. LEE DH, Yu EJ, Aldahl J, Yang J, et al
    Deletion of the p16INK4a tumor suppressor and expression of the androgen receptor induce sarcomatoid carcinomas with signet ring cells in the mouse prostate.
    PLoS One. 2019;14:e0211153.
    PubMed     Abstract available

  143. LIU X, Wiersma RD
    Optimization based trajectory planning for real-time 6DoF robotic patient motion compensation systems.
    PLoS One. 2019;14:e0210385.
    PubMed     Abstract available

  144. BUGLIONE M, Noale M, Bruni A, Antonelli A, et al
    Treatment paths for localised prostate cancer in Italy: The results of a multidisciplinary, observational, prospective study (Pros-IT CNR).
    PLoS One. 2019;14:e0224151.
    PubMed     Abstract available

  145. MAAHS L, Sanchez BE, Gupta N, Van Harn M, et al
    Class III beta-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer.
    PLoS One. 2019;14:e0222510.
    PubMed     Abstract available

  146. BYUN SS, Lee M, Hong SK, Lee H, et al
    Elevated Ki-67 (MIB-1) expression as an independent predictor for unfavorable pathologic outcomes and biochemical recurrence after radical prostatectomy in patients with localized prostate cancer: A propensity score matched study.
    PLoS One. 2019;14:e0224671.
    PubMed     Abstract available

  147. YOU D, Kim Y, Jang MJ, Lee C, et al
    Correction: KML001 Induces Apoptosis and Autophagic Cell Death in Prostate Cancer Cells via Oxidative Stress Pathway.
    PLoS One. 2019;14:e0225087.
    PubMed     Abstract available

  148. VERMA S, Pandey M, Shukla GC, Singh V, et al
    Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer.
    PLoS One. 2019;14:e0224071.
    PubMed     Abstract available

  149. SEAMAN AT, Taylor KL, Davis K, Nepple KG, et al
    Why men with a low-risk prostate cancer select and stay on active surveillance: A qualitative study.
    PLoS One. 2019;14:e0225134.
    PubMed     Abstract available

  150. ZHENG S, Jiang S, Chen Z, Huang Z, et al
    The roles of MRI-based prostate volume and associated zone-adjusted prostate-specific antigen concentrations in predicting prostate cancer and high-risk prostate cancer.
    PLoS One. 2019;14:e0218645.
    PubMed     Abstract available

  151. WETTERAUER C, Winkel DJ, Federer-Gsponer JR, Halla A, et al
    Structured reporting of prostate magnetic resonance imaging has the potential to improve interdisciplinary communication.
    PLoS One. 2019;14:e0212444.
    PubMed     Abstract available

  152. COSMA I, Tennstedt-Schenk C, Winzler S, Psychogios MN, et al
    The role of gadolinium in magnetic resonance imaging for early prostate cancer diagnosis: A diagnostic accuracy study.
    PLoS One. 2019;14:e0227031.
    PubMed     Abstract available

  153. BEER L, Polanec SH, Baltzer PAT, Schatzl G, et al
    4D perfusion CT of prostate cancer for image-guided radiotherapy planning: A proof of concept study.
    PLoS One. 2019;14:e0225673.
    PubMed     Abstract available

  154. ZHANG H, Gordon R, Li W, Yang X, et al
    Genistein treatment duration effects biomarkers of cell motility in human prostate.
    PLoS One. 2019;14:e0214078.
    PubMed     Abstract available

  155. BOUTTELL J, Teoh J, Chiu PK, Chan KS, et al
    Economic evaluation of the introduction of the Prostate Health Index as a rule-out test to avoid unnecessary biopsies in men with prostate specific antigen levels of 4-10 in Hong Kong.
    PLoS One. 2019;14:e0215279.
    PubMed     Abstract available

  156. DURST MA, Ratia K, Lavie A
    Identifying small molecule probes of ENTPD5 through high throughput screening.
    PLoS One. 2019;14:e0210305.
    PubMed     Abstract available

  157. SIROHI D, Devine P, Grenert JP, van Ziffle J, et al
    TP53 structural variants in metastatic prostatic carcinoma.
    PLoS One. 2019;14:e0218618.
    PubMed     Abstract available

  158. RABIN-COURT A, Rodrigues MR, Zhang XM, Perry RJ, et al
    Obesity-associated, but not obesity-independent, tumors respond to insulin by increasing mitochondrial glucose oxidation.
    PLoS One. 2019;14:e0218126.
    PubMed     Abstract available

  159. SZCZUREK L, Juszkat R, Szczurek J, Turek I, et al
    Pre-treatment 2D and 3D dosimetric verification of volumetric arc therapy. A correlation study between gamma index passing rate and clinical dose volume histogram.
    PLoS One. 2019;14:e0221086.
    PubMed     Abstract available

  160. LU S, Dong Z
    Additive effects of a small molecular PCNA inhibitor PCNA-I1S and DNA damaging agents on growth inhibition and DNA damage in prostate and lung cancer cells.
    PLoS One. 2019;14:e0223894.
    PubMed     Abstract available

  161. HONG Y, Lee S, Won S
    The preventive effect of metformin on progression of benign prostate hyperplasia: A nationwide population-based cohort study in Korea.
    PLoS One. 2019;14:e0219394.
    PubMed     Abstract available

  162. TAN JWY, Murashov MD, Rosania GR, Wang X, et al
    Photoacoustic imaging of clofazimine hydrochloride nanoparticle accumulation in cancerous vs normal prostates.
    PLoS One. 2019;14:e0219655.
    PubMed     Abstract available

  163. KATSOGIANNOU M, Boyer JB, Valdeolivas A, Remy E, et al
    Integrative proteomic and phosphoproteomic profiling of prostate cell lines.
    PLoS One. 2019;14:e0224148.
    PubMed     Abstract available

  164. BECK S, Borutta B, Walter U, Dreier M, et al
    Systematic evaluation of written health information on PSA based screening in Germany.
    PLoS One. 2019;14:e0220745.
    PubMed     Abstract available

  165. PAL G, Ogunwobi OO
    Copy number-based quantification assay for non-invasive detection of PVT1-derived transcripts.
    PLoS One. 2019;14:e0226620.
    PubMed     Abstract available

  166. SU SY, Lee WC
    Age-period-cohort analysis with a constant-relative-variation constraint for an apportionment of period and cohort slopes.
    PLoS One. 2019;14:e0226678.
    PubMed     Abstract available

  167. PATEL DI, Abuchowski K, Bedolla R, Rivas P, et al
    Nexrutine and exercise similarly prevent high grade prostate tumors in transgenic mouse model.
    PLoS One. 2019;14:e0226187.
    PubMed     Abstract available

  168. SHARMA D, Giles A, Hashim A, Yip J, et al
    Ultrasound microbubble potentiated enhancement of hyperthermia-effect in tumours.
    PLoS One. 2019;14:e0226475.
    PubMed     Abstract available

  169. BOOTH N, Rissanen P, Tammela TLJ, Kujala P, et al
    Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
    PLoS One. 2019;14:e0224479.
    PubMed     Abstract available

    January 2018
  170. YANG F, Yu N, Wang H, Zhang C, et al
    Downregulated expression of hepatoma-derived growth factor inhibits migration and invasion of prostate cancer cells by suppressing epithelial-mesenchymal transition and MMP2, MMP9.
    PLoS One. 2018;13:e0190725.
    PubMed     Abstract available

  171. SRIVASTAVA P, Sarma A, Chaturvedi CM
    Targeting DNA repair with PNKP inhibition sensitizes radioresistant prostate cancer cells to high LET radiation.
    PLoS One. 2018;13:e0190516.
    PubMed     Abstract available

  172. BYUN SJ, Kim YS, Ahn H, Kim CS, et al
    Image-guided, whole-pelvic, intensity-modulated radiotherapy for biochemical recurrence following radical prostatectomy in high-risk prostate cancer patients.
    PLoS One. 2018;13:e0190479.
    PubMed     Abstract available

  173. BARAKAT DJ, Suresh R, Barberi T, Pienta KJ, et al
    Absence of myeloid Klf4 reduces prostate cancer growth with pro-atherosclerotic activation of tumor myeloid cells and infiltration of CD8 T cells.
    PLoS One. 2018;13:e0191188.
    PubMed     Abstract available

  174. HAYES AR, Brungs D, Pavlakis N
    Osteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0191455.
    PubMed     Abstract available

  175. KORONOWICZ AA, Drozdowska M, Wielgos B, Piasna-Slupecka E, et al
    The effect of "NutramilTM Complex," food for special medical purpose, on breast and prostate carcinoma cells.
    PLoS One. 2018;13:e0192860.
    PubMed     Abstract available

  176. GILLEBERT Q, Huchet V, Rousseau C, Cochet A, et al
    18F-fluorocholine PET/CT in patients with occult biochemical recurrence of prostate cancer: Detection rate, impact on management and adequacy of impact. A prospective multicentre study.
    PLoS One. 2018;13:e0191487.
    PubMed     Abstract available

  177. JAYARAMAN A, Kumar P, Marin S, de Atauri P, et al
    Untargeted metabolomics reveals distinct metabolic reprogramming in endothelial cells co-cultured with CSC and non-CSC prostate cancer cell subpopulations.
    PLoS One. 2018;13:e0192175.
    PubMed     Abstract available

  178. EGGER S, Hughes S, Smith DP, Chambers S, et al
    Factors associated with the use of complementary and alternative medicines for prostate cancer by long-term survivors.
    PLoS One. 2018;13:e0193686.
    PubMed     Abstract available

  179. SHIN H, Park YH, Kim YG, Lee JY, et al
    Aqueous two-phase system to isolate extracellular vesicles from urine for prostate cancer diagnosis.
    PLoS One. 2018;13:e0194818.
    PubMed     Abstract available

  180. RUSSELL B, Garmo H, Beckmann K, Stattin P, et al
    A case-control study of lower urinary-tract infections, associated antibiotics and the risk of developing prostate cancer using PCBaSe 3.0.
    PLoS One. 2018;13:e0195690.
    PubMed     Abstract available

  181. FRYZEK JP, Reichert H, Summers N, Townes L, et al
    Indirect treatment comparison of cabazitaxel for patients with metastatic castrate-resistant prostate cancer who have been previously treated with a docetaxel-containing regimen.
    PLoS One. 2018;13:e0195790.
    PubMed     Abstract available

  182. GOINEAU A, Campion L, d'Aillieres B, Vie B, et al
    Comprehensive Geriatric Assessment and quality of life after localized prostate cancer radiotherapy in elderly patients.
    PLoS One. 2018;13:e0194173.
    PubMed     Abstract available

  183. CAMPBELL DH, Lund ME, Nocon AL, Cozzi PJ, et al
    Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.
    PLoS One. 2018;13:e0196017.
    PubMed     Abstract available

  184. WALSH DMJ, Groarke AM, Morrison TG, Durkan G, et al
    Measuring a new facet of post traumatic growth: Development of a scale of physical post traumatic growth in men with prostate cancer.
    PLoS One. 2018;13:e0195992.
    PubMed     Abstract available

  185. CHEUNG S, Hamuro Y, Mahlich J, Nakayama M, et al
    Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data.
    PLoS One. 2018;13:e0195789.
    PubMed     Abstract available

  186. SCHWEIZER MT, Haugk K, McKiernan JS, Gulati R, et al
    A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
    PLoS One. 2018;13:e0198389.
    PubMed     Abstract available

  187. MARU S, Uchino H, Osawa T, Chiba S, et al
    Long-term treatment outcomes of intermittent androgen deprivation therapy for relapsed prostate cancer after radical prostatectomy.
    PLoS One. 2018;13:e0197252.
    PubMed     Abstract available

  188. SMITH DP, Calopedos R, Bang A, Yu XQ, et al
    Increased risk of suicide in New South Wales men with prostate cancer: Analysis of linked population-wide data.
    PLoS One. 2018;13:e0198679.
    PubMed     Abstract available

  189. PARK JW, Koh DH, Jang WS, Lee JY, et al
    Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients.
    PLoS One. 2018;13:e0199365.
    PubMed     Abstract available

  190. KARUNASINGHE N, Ambs S, Wang A, Tang W, et al
    Influence of lifestyle and genetic variants in the aldo-keto reductase 1C3 rs12529 polymorphism in high-risk prostate cancer detection variability assessed between US and New Zealand cohorts.
    PLoS One. 2018;13:e0199122.
    PubMed     Abstract available

  191. EBBING J, Jaderling F, Collins JW, Akre O, et al
    Comparison of 3D printed prostate models with standard radiological information to aid understanding of the precise location of prostate cancer: A construct validation study.
    PLoS One. 2018;13:e0199477.
    PubMed     Abstract available

  192. LEE H, Hwang SI, Lee HJ, Byun SS, et al
    Diagnostic performance of diffusion-weighted imaging for prostate cancer: Peripheral zone versus transition zone.
    PLoS One. 2018;13:e0199636.
    PubMed     Abstract available

  193. WALSH TJ, Shores MM, Krakauer CA, Forsberg CW, et al
    Testosterone treatment and the risk of aggressive prostate cancer in men with low testosterone levels.
    PLoS One. 2018;13:e0199194.
    PubMed     Abstract available

  194. FERRARINI A, Forcato C, Buson G, Tononi P, et al
    A streamlined workflow for single-cells genome-wide copy-number profiling by low-pass sequencing of LM-PCR whole-genome amplification products.
    PLoS One. 2018;13:e0193689.
    PubMed     Abstract available

  195. BOURKE L, Turner R, Greasley R, Sutton E, et al
    A multi-centre investigation of delivering national guidelines on exercise training for men with advanced prostate cancer undergoing androgen deprivation therapy in the UK NHS.
    PLoS One. 2018;13:e0197606.
    PubMed     Abstract available

  196. DANKERT JT, Wiesehofer M, Czyrnik ED, Singer BB, et al
    The deregulation of miR-17/CCND1 axis during neuroendocrine transdifferentiation of LNCaP prostate cancer cells.
    PLoS One. 2018;13:e0200472.
    PubMed     Abstract available

  197. KOITSALU M, Eklund M, Adolfsson J, Sprangers MAG, et al
    Predictors of participation in risk-based prostate cancer screening.
    PLoS One. 2018;13:e0200409.
    PubMed     Abstract available

  198. PRITCHARD AL, Johansson PA, Nathan V, Howlie M, et al
    Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
    PLoS One. 2018;13:e0194098.
    PubMed     Abstract available

  199. NAIR-SHALLIKER V, Egger S, Chrzanowska A, Mason R, et al
    Associations between sun sensitive pigmentary genes and serum prostate specific antigen levels.
    PLoS One. 2018;13:e0193893.
    PubMed     Abstract available

  200. SCHAAKE W, van der Schaaf A, van Dijk LV, van den Bergh ACM, et al
    Development of a prediction model for late urinary incontinence, hematuria, pain and voiding frequency among irradiated prostate cancer patients.
    PLoS One. 2018;13:e0197757.
    PubMed     Abstract available

  201. TENTORI K, Pighin S, Divan C, Crupi V, et al
    Mind the gap: Physicians' assessment of patients' importance weights in localized prostate cancer.
    PLoS One. 2018;13:e0200780.
    PubMed     Abstract available

  202. BIALKOWSKA K, Marciniak W, Muszynska M, Baszuk P, et al
    Association of zinc level and polymorphism in MMP-7 gene with prostate cancer in Polish population.
    PLoS One. 2018;13:e0201065.
    PubMed     Abstract available

  203. HILLEBRAND AC, Pizzolato LS, Neto BS, Branchini G, et al
    Androgen receptor isoforms expression in benign prostatic hyperplasia and primary prostate cancer.
    PLoS One. 2018;13:e0200613.
    PubMed     Abstract available

  204. JANSEN RJ, Alexander BH, Hayes RB, Miller AB, et al
    A mathematical model of case-ascertainment bias: Applied to case-control studies nested within a randomized screening trial.
    PLoS One. 2018;13:e0194608.
    PubMed     Abstract available

  205. PUNNEN S, Nahar B, Soodana-Prakash N, Koru-Sengul T, et al
    Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer.
    PLoS One. 2018;13:e0201384.
    PubMed     Abstract available

  206. KOIKE Y, Sumida I, Mizuno H, Shiomi H, et al
    Dosimetric impact of intra-fraction prostate motion under a tumour-tracking system in hypofractionated robotic radiosurgery.
    PLoS One. 2018;13:e0195296.
    PubMed     Abstract available

  207. SCHWEIZER MT, Haugk K, McKiernan JS, Gulati R, et al
    Correction: A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.
    PLoS One. 2018;13:e0202709.
    PubMed     Abstract available

  208. YE Y, Li SL, Wang SY
    Construction and analysis of mRNA, miRNA, lncRNA, and TF regulatory networks reveal the key genes associated with prostate cancer.
    PLoS One. 2018;13:e0198055.
    PubMed     Abstract available

  209. BRIDGES D, Kawamura H, Kanai T
    Probabilistic dose distribution from interfractional motion in carbon ion radiation therapy for prostate cancer shows rectum sparing with moderate target coverage degradation.
    PLoS One. 2018;13:e0203289.
    PubMed     Abstract available

  210. PENZIAS G, Singanamalli A, Elliott R, Gollamudi J, et al
    Identifying the morphologic basis for radiomic features in distinguishing different Gleason grades of prostate cancer on MRI: Preliminary findings.
    PLoS One. 2018;13:e0200730.
    PubMed     Abstract available

  211. KIM JJ, Kim T, Lee H, Byun SS, et al
    Prediction of unilateral prostate cancer by the combination of transrectal ultrasonography-guided prostate biopsy and multi-parametric magnetic resonance imaging: A real-life experience.
    PLoS One. 2018;13:e0202872.
    PubMed     Abstract available

  212. GUO Y, Wang L, Hu J, Feng D, et al
    Diagnostic performance of choline PET/CT for the detection of bone metastasis in prostate cancer: A systematic review and meta-analysis.
    PLoS One. 2018;13:e0203400.
    PubMed     Abstract available

  213. LIN HW, Lin LF, Chen HC, Liou TH, et al
    Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach.
    PLoS One. 2018;13:e0203377.
    PubMed     Abstract available

  214. HASAN D, Gamen E, Abu Tarboush N, Ismail Y, et al
    PKM2 and HIF-1alpha regulation in prostate cancer cell lines.
    PLoS One. 2018;13:e0203745.
    PubMed     Abstract available

  215. MOSES-FYNN E, Tang W, Beyene D, Apprey V, et al
    Correlating blood-based DNA methylation markers and prostate cancer risk in African-American men.
    PLoS One. 2018;13:e0203322.
    PubMed     Abstract available

  216. CHOI YJ, Lee DH, Han KD, Yoon H, et al
    Is nonalcoholic fatty liver disease associated with the development of prostate cancer? A nationwide study with 10,516,985 Korean men.
    PLoS One. 2018;13:e0201308.
    PubMed     Abstract available

  217. MILOSAVLJEVIC V, Haddad Y, Merlos Rodrigo MA, Moulick A, et al
    Correction: The Zinc-Schiff Base-Novicidin Complex as a Potential Prostate Cancer Therapy.
    PLoS One. 2018;13:e0204441.
    PubMed     Abstract available

  218. LEIGHTON X, Bera A, Eidelman O, Bubendorf L, et al
    Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.
    PLoS One. 2018;13:e0205837.
    PubMed     Abstract available

  219. WU X, Zhang K, Chen Y, Wang R, et al
    Theoretical and experimental study of dual-fiber laser ablation for prostate cancer.
    PLoS One. 2018;13:e0206065.
    PubMed     Abstract available

  220. BABALYAN K, Sultanov R, Generozov E, Sharova E, et al
    LogLoss-BERAF: An ensemble-based machine learning model for constructing highly accurate diagnostic sets of methylation sites accounting for heterogeneity in prostate cancer.
    PLoS One. 2018;13:e0204371.
    PubMed     Abstract available

  221. ZHANG S, Zheng C, Yao S, Wang Z, et al
    Proteomic analysis of human prostate cancer PC-3M-1E8 cells and PC-3M-2B4 cells of same origin but with different metastatic potential.
    PLoS One. 2018;13:e0206139.
    PubMed     Abstract available

  222. ZHANG X, Lin Y, Xie X, Shen M, et al
    Is acne in adolescence associated with prostate cancer risk? Evidence from a meta-analysis.
    PLoS One. 2018;13:e0206249.
    PubMed     Abstract available

  223. VARNAVA M, Sumida I, Mizuno H, Shiomi H, et al
    A new plan quality objective function for determining optimal collimator combinations in prostate cancer treatment with stereotactic body radiation therapy using CyberKnife.
    PLoS One. 2018;13:e0208086.
    PubMed     Abstract available

  224. CHIU TD, Arai TJ, Campbell Iii J, Jiang SB, et al
    MR-CBCT image-guided system for radiotherapy of orthotopic rat prostate tumors.
    PLoS One. 2018;13:e0198065.
    PubMed     Abstract available

  225. GROCHTDREIS T, Konig HH, Dobruschkin A, von Amsberg G, et al
    Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
    PLoS One. 2018;13:e0208063.
    PubMed     Abstract available

  226. HUANG MH, Blackwood J, Godoshian M, Pfalzer L, et al
    Factors associated with self-reported falls, balance or walking difficulty in older survivors of breast, colorectal, lung, or prostate cancer: Results from Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey linkage.
    PLoS One. 2018;13:e0208573.
    PubMed     Abstract available

  227. TINZL M, Chen B, Chen SY, Semenas J, et al
    Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer.
    PLoS One. 2018;13:e0209544.
    PubMed     Abstract available

  228. PARK JW, Lee JH, Cho HJ, Ha YJ, et al
    Influence of androgen deprivation therapy on serum urate levels in patients with prostate cancer: A retrospective observational study.
    PLoS One. 2018;13:e0209049.
    PubMed     Abstract available

  229. CHUNG DY, Goh HJ, Koh DH, Kim MS, et al
    Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer.
    PLoS One. 2018;13:e0210037.
    PubMed     Abstract available

  230. FONSECA-ALVES CE, Kobayashi PE, Rivera Calderon LG, Felisbino SL, et al
    Immunohistochemical panel to characterize canine prostate carcinomas according to aberrant p63 expression.
    PLoS One. 2018;13:e0199173.
    PubMed     Abstract available

  231. GUPTA S, Silveira DA, Mombach JCM
    Modeling the role of microRNA-449a in the regulation of the G2/M cell cycle checkpoint in prostate LNCaP cells under ionizing radiation.
    PLoS One. 2018;13:e0200768.
    PubMed     Abstract available

  232. ARAS O, Pearce G, Watkins AJ, Nurili F, et al
    An in-vivo pilot study into the effects of FDG-mNP in cancer in mice.
    PLoS One. 2018;13:e0202482.
    PubMed     Abstract available

  233. GOMEZ-ACEBO I, Dierssen-Sotos T, Palazuelos C, Fernandez-Navarro P, et al
    Pigmentation phototype and prostate and breast cancer in a select Spanish population-A Mendelian randomization analysis in the MCC-Spain study.
    PLoS One. 2018;13:e0201750.
    PubMed     Abstract available

  234. HERNANDEZ J, Gelfond J, Goros M, Liss MA, et al
    The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial.
    PLoS One. 2018;13:e0204823.
    PubMed     Abstract available

  235. LU DL, Ren ZJ, Zhang Q, Ren PW, et al
    Meta-analysis of the association between the inflammatory potential of diet and urologic cancer risk.
    PLoS One. 2018;13:e0204845.
    PubMed     Abstract available

  236. BURTON LJ, Hawsawi O, Loyd Q, Henderson V, et al
    Association of Epithelial Mesenchymal Transition with prostate and breast health disparities.
    PLoS One. 2018;13:e0203855.
    PubMed     Abstract available

  237. DE SILVA D, Ranasinghe W, Bandaragoda T, Adikari A, et al
    Machine learning to support social media empowered patients in cancer care and cancer treatment decisions.
    PLoS One. 2018;13:e0205855.
    PubMed     Abstract available

  238. BALLARINI NM, Rosenkranz GK, Jaki T, Konig F, et al
    Subgroup identification in clinical trials via the predicted individual treatment effect.
    PLoS One. 2018;13:e0205971.
    PubMed     Abstract available

  239. MAUGHAM ML, Seim I, Thomas PB, Crisp GJ, et al
    No effect of unacylated ghrelin administration on subcutaneous PC3 xenograft growth or metabolic parameters in a Rag1-/- mouse model of metabolic dysfunction.
    PLoS One. 2018;13:e0198495.
    PubMed     Abstract available

  240. STRANDBERG S, Hashemi A, Axelsson J, Riklund K, et al
    Optimization of PET reconstruction algorithm, SUV thresholding algorithm and PET acquisition time in clinical 11C-acetate PET/CT.
    PLoS One. 2018;13:e0209169.
    PubMed     Abstract available

  241. HAMMES J, Hohberg M, Tager P, Wild M, et al
    Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT.
    PLoS One. 2018;13:e0209613.
    PubMed     Abstract available

    January 2017
  242. SEO Y, Ryu K, Park J, Jeon DK, et al
    Inhibition of ANO1 by luteolin and its cytotoxicity in human prostate cancer PC-3 cells.
    PLoS One. 2017;12:e0174935.
    PubMed     Abstract available

  243. LE B, Powers GL, Tam YT, Schumacher N, et al
    Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
    PLoS One. 2017;12:e0174658.
    PubMed     Abstract available

  244. LYNCH SM, Mitra N, Ross M, Newcomb C, et al
    A Neighborhood-Wide Association Study (NWAS): Example of prostate cancer aggressiveness.
    PLoS One. 2017;12:e0174548.
    PubMed     Abstract available

  245. FAN CY, Huang WY, Lin CS, Su YF, et al
    Risk of second primary malignancies among patients with prostate cancer: A population-based cohort study.
    PLoS One. 2017;12:e0175217.
    PubMed     Abstract available

  246. Correction: Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    PLoS One. 2017;12:e0175606.
    PubMed     Abstract available

  247. PANG KH, Rosario DJ, Morgan SL, Catto JW, et al
    Evaluation of a short RNA within Prostate Cancer Gene 3 in the predictive role for future cancer using non-malignant prostate biopsies.
    PLoS One. 2017;12:e0175070.
    PubMed     Abstract available

  248. ROHENA-RIVERA K, Sanchez-Vazquez MM, Aponte-Colon DA, Forestier-Roman IS, et al
    IL-15 regulates migration, invasion, angiogenesis and genes associated with lipid metabolism and inflammation in prostate cancer.
    PLoS One. 2017;12:e0172786.
    PubMed     Abstract available

  249. MARTINEZ-MARIN D, Jarvis C, Nelius T, de Riese W, et al
    PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro.
    PLoS One. 2017;12:e0174968.
    PubMed     Abstract available

  250. ONUKWUGHA E, Kwok Y, Ciezki JP, Yong C, et al
    Skeletal-related events and mortality among men diagnosed with advanced prostate cancer: The impact of alternative measures of radiation to the bone.
    PLoS One. 2017;12:e0175956.
    PubMed     Abstract available

  251. AL AAMERI RFH, Sheth S, Alanisi EMA, Borse V, et al
    Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.
    PLoS One. 2017;12:e0177198.
    PubMed     Abstract available

  252. OKEYO-OWUOR T, Benesh E, Bibbey S, Reid M, et al
    Exposure to maternal obesogenic diet worsens some but not all pre-cancer phenotypes in a murine genetic model of prostate cancer.
    PLoS One. 2017;12:e0175764.
    PubMed     Abstract available

  253. SCHUBERT C, Waletzko O, Weiss C, Voelzke D, et al
    Intercenter validation of a knowledge based model for automated planning of volumetric modulated arc therapy for prostate cancer. The experience of the German RapidPlan Consortium.
    PLoS One. 2017;12:e0178034.
    PubMed     Abstract available

  254. TENNILL TA, Gross ME, Frieboes HB
    Automated analysis of co-localized protein expression in histologic sections of prostate cancer.
    PLoS One. 2017;12:e0178362.
    PubMed     Abstract available

  255. DELOBEL JB, Gnep K, Ospina JD, Beckendorf V, et al
    Nomogram to predict rectal toxicity following prostate cancer radiotherapy.
    PLoS One. 2017;12:e0179845.
    PubMed     Abstract available

  256. RIVERA M, Ramos Y, Rodriguez-Valentin M, Lopez-Acevedo S, et al
    Targeting multiple pro-apoptotic signaling pathways with curcumin in prostate cancer cells.
    PLoS One. 2017;12:e0179587.
    PubMed     Abstract available

  257. ZEDAN AH, Blavnsfeldt SG, Hansen TF, Nielsen BS, et al
    Heterogeneity of miRNA expression in localized prostate cancer with clinicopathological correlations.
    PLoS One. 2017;12:e0179113.
    PubMed     Abstract available

  258. PASHAEI E, Pashaei E, Ahmady M, Ozen M, et al
    Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.
    PLoS One. 2017;12:e0179543.
    PubMed     Abstract available

  259. ROY A, Ramalinga M, Kim OJ, Chijioke J, et al
    Multiple roles of RARRES1 in prostate cancer: Autophagy induction and angiogenesis inhibition.
    PLoS One. 2017;12:e0180344.
    PubMed     Abstract available

  260. POLANEC SH, Andrzejewski P, Baltzer PAT, Helbich TH, et al
    Multiparametric [11C]Acetate positron emission tomography-magnetic resonance imaging in the assessment and staging of prostate cancer.
    PLoS One. 2017;12:e0180790.
    PubMed     Abstract available

  261. ZHANG Y, Su X, Kong Z, Fu F, et al
    An androgen reduced transcript of LncRNA GAS5 promoted prostate cancer proliferation.
    PLoS One. 2017;12:e0182305.
    PubMed     Abstract available

  262. ENDT K, Goepfert J, Omlin A, Athanasiou A, et al
    Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.
    PLoS One. 2017;12:e0181557.
    PubMed     Abstract available

  263. ZHANG ZH, Xie DD, Xu S, Xia MZ, et al
    Total glucosides of paeony inhibits lipopolysaccharide-induced proliferation, migration and invasion in androgen insensitive prostate cancer cells.
    PLoS One. 2017;12:e0182584.
    PubMed     Abstract available

  264. WANG K, Jin S, Fan D, Wang M, et al
    Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene.
    PLoS One. 2017;12:e0172233.
    PubMed     Abstract available

  265. SUMIDA I, Yamaguchi H, Das IJ, Anetai Y, et al
    Robust plan optimization using edge-enhanced intensity for intrafraction organ deformation in prostate intensity-modulated radiation therapy.
    PLoS One. 2017;12:e0173643.
    PubMed     Abstract available

  266. ZHAN W, Gedroyc W, Xu XY
    The effect of tumour size on drug transport and uptake in 3-D tumour models reconstructed from magnetic resonance images.
    PLoS One. 2017;12:e0172276.
    PubMed     Abstract available

  267. LI SL, Ye Y, Yuan XH
    Association between Allogeneic or Autologous Blood Transfusion and Survival in Patients after Radical Prostatectomy: A Systematic Review and Meta-Analysis.
    PLoS One. 2017;12:e0171081.
    PubMed     Abstract available

  268. ZHOU J, Gao S, Hsieh CL, Malla M, et al
    Peptide B targets soluble guanylyl cyclase alpha1 and kills prostate cancer cells.
    PLoS One. 2017;12:e0184088.
    PubMed     Abstract available

  269. LUCAS JL, Tacheny EA, Ferris A, Galusha M, et al
    Development and validation of a Luminex assay for detection of a predictive biomarker for PROSTVAC-VF therapy.
    PLoS One. 2017;12:e0182739.
    PubMed     Abstract available

  270. CANESIN G, Evans-Axelsson S, Hellsten R, Krzyzanowska A, et al
    Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model.
    PLoS One. 2017;12:e0184418.
    PubMed     Abstract available

  271. GUI B, Hsieh CL, Kantoff PW, Kibel AS, et al
    Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.
    PLoS One. 2017;12:e0184166.
    PubMed     Abstract available

  272. READY D, Yagiz K, Amin P, Yildiz Y, et al
    Mapping the STK4/Hippo signaling network in prostate cancer cell.
    PLoS One. 2017;12:e0184590.
    PubMed     Abstract available

  273. Correction: Evaluation of different mathematical models and different b-value ranges of diffusion-weighted imaging in peripheral zone prostate cancer detection using b-value up to 4500 s/mm2.
    PLoS One. 2017;12:e0184609.
    PubMed     Abstract available

  274. LIAO JM, Ommerborn MJ, Clark CR
    Association between features of patient-provider discussions and routine prostate-specific antigen testing.
    PLoS One. 2017;12:e0177687.
    PubMed     Abstract available

  275. KARLSSON J, Gouveia-Figueira S, Alhouayek M, Fowler CJ, et al
    Effects of tumour necrosis factor alpha upon the metabolism of the endocannabinoid anandamide in prostate cancer cells.
    PLoS One. 2017;12:e0185011.
    PubMed     Abstract available

  276. SOUZA MF, Kuasne H, Barros-Filho MC, Ciliao HL, et al
    Circulating mRNAs and miRNAs as candidate markers for the diagnosis and prognosis of prostate cancer.
    PLoS One. 2017;12:e0184094.
    PubMed     Abstract available

  277. KANG M, Lee KH, Lee HS, Jeong CW, et al
    Concurrent treatment with simvastatin and NF-kappaB inhibitor in human castration-resistant prostate cancer cells exerts synergistic anti-cancer effects via control of the NF-kappaB/LIN28/let-7 miRNA signaling pathway.
    PLoS One. 2017;12:e0184644.
    PubMed     Abstract available

  278. OPOKU-ACHEAMPONG AB, Henningson JN, Beck AP, Lindshield BL, et al
    5alpha-reductase 1 mRNA levels are positively correlated with TRAMP mouse prostate most severe lesion scores.
    PLoS One. 2017;12:e0175874.
    PubMed     Abstract available

  279. LUO Q, Egger S, Yu XQ, Smith DP, et al
    Validity of using multiple imputation for "unknown" stage at diagnosis in population-based cancer registry data.
    PLoS One. 2017;12:e0180033.
    PubMed     Abstract available

  280. LAISECA JE, Ladelfa MF, Cotignola J, Peche LY, et al
    Functional interaction between co-expressed MAGE-A proteins.
    PLoS One. 2017;12:e0178370.
    PubMed     Abstract available

  281. ZLITNI A, Yin M, Janzen N, Chatterjee S, et al
    Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry.
    PLoS One. 2017;12:e0176958.
    PubMed     Abstract available

  282. STROMVALL K, Thysell E, Halin Bergstrom S, Bergh A, et al
    Aggressive rat prostate tumors reprogram the benign parts of the prostate and regional lymph nodes prior to metastasis.
    PLoS One. 2017;12:e0176679.
    PubMed     Abstract available

  283. ZHAO A, Chen F, Ning C, Wu H, et al
    Use of real-time cellular analysis and Plackett-Burman design to develop the serum-free media for PC-3 prostate cancer cells.
    PLoS One. 2017;12:e0185470.
    PubMed     Abstract available

  284. ROUVIERE O, Dagonneau T, Cros F, Bratan F, et al
    Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers.
    PLoS One. 2017;12:e0178901.
    PubMed     Abstract available

  285. REULEN RC, de Vogel S, Zhong W, Zhong Z, et al
    Physical activity and risk of prostate and bladder cancer in China: The South and East China case-control study on prostate and bladder cancer.
    PLoS One. 2017;12:e0178613.
    PubMed     Abstract available

  286. YU EJ, Hooker E, Johnson DT, Kwak MK, et al
    LZTS2 and PTEN collaboratively regulate ss-catenin in prostatic tumorigenesis.
    PLoS One. 2017;12:e0174357.
    PubMed     Abstract available

  287. KHAN S, Simpson J, Lynch JC, Turay D, et al
    Racial differences in the expression of inhibitors of apoptosis (IAP) proteins in extracellular vesicles (EV) from prostate cancer patients.
    PLoS One. 2017;12:e0183122.
    PubMed     Abstract available

  288. ROBLES-FERNANDEZ I, Martinez-Gonzalez LJ, Pascual-Geler M, Cozar JM, et al
    Association between polymorphisms in sex hormones synthesis and metabolism and prostate cancer aggressiveness.
    PLoS One. 2017;12:e0185447.
    PubMed     Abstract available

  289. MURPHY C, Rettedal E, Lehouritis P, Devoy C, et al
    Intratumoural production of TNFalpha by bacteria mediates cancer therapy.
    PLoS One. 2017;12:e0180034.
    PubMed     Abstract available

  290. THON A, Teichgraber U, Tennstedt-Schenk C, Hadjidemetriou S, et al
    Computer aided detection in prostate cancer diagnostics: A promising alternative to biopsy? A retrospective study from 104 lesions with histological ground truth.
    PLoS One. 2017;12:e0185995.
    PubMed     Abstract available

  291. MORLANDO M, Pelullo CP, Di Giuseppe G
    Prostate cancer screening: Knowledge, attitudes and practices in a sample of men in Italy. A survey.
    PLoS One. 2017;12:e0186332.
    PubMed     Abstract available

  292. LEAPMAN MS, Westphalen AC, Ameli N, Lawrence HJ, et al
    Association between a 17-gene genomic prostate score and multi-parametric prostate MRI in men with low and intermediate risk prostate cancer (PCa).
    PLoS One. 2017;12:e0185535.
    PubMed     Abstract available

  293. ARTHURS C, Murtaza BN, Thomson C, Dickens K, et al
    Expression of ribosomal proteins in normal and cancerous human prostate tissue.
    PLoS One. 2017;12:e0186047.
    PubMed     Abstract available

  294. HEBBRECHT T, Van Audenhove I, Zwaenepoel O, Verhelle A, et al
    VCA nanobodies target N-WASp to reduce invadopodium formation and functioning.
    PLoS One. 2017;12:e0185076.
    PubMed     Abstract available

  295. AL-MAHROUKI A, Giles A, Hashim A, Kim HC, et al
    Microbubble-based enhancement of radiation effect: Role of cell membrane ceramide metabolism.
    PLoS One. 2017;12:e0181951.
    PubMed     Abstract available

  296. XIAO WJ, Zhu Y, Dai B, Ye DW, et al
    Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy.
    PLoS One. 2017;12:e0187887.
    PubMed     Abstract available

  297. TAUROZZI AJ, Beekharry R, Wantoch M, Labarthe MC, et al
    Spontaneous development of Epstein-Barr Virus associated human lymphomas in a prostate cancer xenograft program.
    PLoS One. 2017;12:e0188228.
    PubMed     Abstract available

  298. JEON HG, Yoo JH, Jeong BC, Seo SI, et al
    Comparative rates of upstaging and upgrading in Caucasian and Korean prostate cancer patients eligible for active surveillance.
    PLoS One. 2017;12:e0186026.
    PubMed     Abstract available

  299. ANDERSEN S, Richardsen E, Rakaee M, Bertilsson H, et al
    Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.
    PLoS One. 2017;12:e0189000.
    PubMed     Abstract available

  300. PASQUIER D, Nickers P, Peiffert D, Maingon P, et al
    Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).
    PLoS One. 2017;12:e0187794.
    PubMed     Abstract available

    Assessment of the prognostic value of the 8th AJCC staging system for patients with clinically staged prostate cancer; A time to sub-classify stage IV?
    PLoS One. 2017;12:e0188450.
    PubMed     Abstract available

  302. JAMES LJ, Wong G, Craig JC, Hanson CS, et al
    Men's perspectives of prostate cancer screening: A systematic review of qualitative studies.
    PLoS One. 2017;12:e0188258.
    PubMed     Abstract available

  303. VONDALOVA BLANAROVA O, Safarikova B, Herudkova J, Krkoska M, et al
    Cisplatin or LA-12 enhance killing effects of TRAIL in prostate cancer cells through Bid-dependent stimulation of mitochondrial apoptotic pathway but not caspase-10.
    PLoS One. 2017;12:e0188584.
    PubMed     Abstract available

  304. STROMVALL K, Lundholm M, Thysell E, Bergh A, et al
    Highly aggressive rat prostate tumors rapidly precondition regional lymph nodes for subsequent metastatic growth.
    PLoS One. 2017;12:e0187086.
    PubMed     Abstract available

  305. JEDROSZKA D, Orzechowska M, Hamouz R, Gorniak K, et al
    Markers of epithelial-to-mesenchymal transition reflect tumor biology according to patient age and Gleason score in prostate cancer.
    PLoS One. 2017;12:e0188842.
    PubMed     Abstract available

  306. RICHARDSEN E, Andersen S, Al-Saad S, Rakaee M, et al
    Evaluation of the proliferation marker Ki-67 in a large prostatectomy cohort.
    PLoS One. 2017;12:e0186852.
    PubMed     Abstract available

  307. KOO K, Brackett CD, Eisenberg EH, Kieffer KA, et al
    Impact of numeracy on understanding of prostate cancer risk reduction in PSA screening.
    PLoS One. 2017;12:e0190357.
    PubMed     Abstract available

  308. EINELUOTO JT, Jarvinen P, Kenttamies A, Kilpelainen TP, et al
    Repeat multiparametric MRI in prostate cancer patients on active surveillance.
    PLoS One. 2017;12:e0189272.
    PubMed     Abstract available

  309. DENSLOW A, Switalska M, Jarosz J, Papiernik D, et al
    Clopidogrel in a combined therapy with anticancer drugs-effect on tumor growth, metastasis, and treatment toxicity: Studies in animal models.
    PLoS One. 2017;12:e0188740.
    PubMed     Abstract available

    January 2016
  310. APRELIKOVA O, Tomlinson CC, Hoenerhoff M, Hixon JA, et al
    Development and Preclinical Application of an Immunocompetent Transplant Model of Basal Breast Cancer with Lung, Liver and Brain Metastases.
    PLoS One. 2016;11:e0155262.
    PubMed     Abstract available

  311. MASOOMPOUR SM, Lankarani KB, Honarvar B, Tabatabaee SH, et al
    Changing Epidemiology of Common Cancers in Southern Iran, 2007-2010: A Cross Sectional Study.
    PLoS One. 2016;11:e0155669.
    PubMed     Abstract available

  312. ONER C, Turgut Cosan D, Colak E
    Estrogen and Androgen Hormone Levels Modulate the Expression of PIWI Interacting RNA in Prostate and Breast Cancer.
    PLoS One. 2016;11:e0159044.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.